358376-02-0

Basic information

• Product Name: 1,5-Benzothiazepin-8-ol, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-5-phenyl-, 1,1-dioxide
• CAS NO: 358376-02-0
• Molecular Formula: C22H29NO3S2
• Molecular Weight: 419.609
• Mol File: 358376-02-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 1,5-Benzothiazepin-8-ol, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-5-phenyl-, 1,1-dioxide(CAS DataBase Reference)
• NIST Chemistry Reference: 1,5-Benzothiazepin-8-ol, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-5-phenyl-, 1,1-dioxide(358376-02-0)
• EPA Substance Registry System: 1,5-Benzothiazepin-8-ol, 3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-(methylthio)-5-phenyl-, 1,1-dioxide(358376-02-0)

Safety Data

• Hazardous Substances Data: 358376-02-0(Hazardous Substances Data)

Upstream product

• 179410-97-0 1,1-dioxo-3-butyl-3-ethyl-5-phenyl-7-bromo-8-hydroxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 179410-96-9 7-bromo-3-n-Butyl-3-ethyl-2,3,4,5-tetrahydro-8-methoxy-5-phenyl-1,5-benzothiazepine-1,1-dioxide 
• 5188-07-8 sodium thiomethoxide 

Downstream Products

• 358375-96-9 1,1-Dioxo-3-butyl-3-ethyl-5-phenyl-7-methylthio-8-ethoxycarbonylmethoxy-2,3,4,5-tetrahydro-1,5-benzothiazepine 

Relevant articles and documents

Benzothiazepine compounds and their use as bile acid modulators

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also r

BENZOTHIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS

The invention relates to 1,5-benzothiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also r

Chemical compounds

The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described. 1